[go: up one dir, main page]

IN2012DN02081A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02081A
IN2012DN02081A IN2081DEN2012A IN2012DN02081A IN 2012DN02081 A IN2012DN02081 A IN 2012DN02081A IN 2081DEN2012 A IN2081DEN2012 A IN 2081DEN2012A IN 2012DN02081 A IN2012DN02081 A IN 2012DN02081A
Authority
IN
India
Prior art keywords
prophylaxis
disorders
preparation
treatment
heteroarylmethyl
Prior art date
Application number
Inventor
Lucking Ulrich
Cleve Arwed
Haendler Bernard
Faus Gimenez Hortensia
Kohr Silke
Irlbacher Horst
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of IN2012DN02081A publication Critical patent/IN2012DN02081A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to substituted (heteroarylmethyl)thiohydantoin compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, and their use for the preparation of medicaments for the treatment and/or prophylaxis of disorders, in particular of prostate cancer.
IN2081DEN2012 2009-09-11 2010-08-28 IN2012DN02081A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075421 2009-09-11
EP10075069 2010-02-17
PCT/EP2010/005297 WO2011029537A1 (en) 2009-09-11 2010-08-28 Sustituted ( heteroarylmethyl ) thiohydantoins as anticancer drugs

Publications (1)

Publication Number Publication Date
IN2012DN02081A true IN2012DN02081A (en) 2015-08-21

Family

ID=42782041

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2081DEN2012 IN2012DN02081A (en) 2009-09-11 2010-08-28

Country Status (28)

Country Link
US (1) US20120251551A1 (en)
EP (1) EP2475653A1 (en)
JP (1) JP2013504523A (en)
KR (1) KR20120065396A (en)
CN (1) CN102639523A (en)
AR (1) AR078166A1 (en)
AU (1) AU2010294588A1 (en)
BR (1) BR112012005526A2 (en)
CA (1) CA2773591A1 (en)
CL (1) CL2012000623A1 (en)
CO (1) CO6511228A2 (en)
CR (1) CR20120113A (en)
CU (1) CU20120042A7 (en)
DO (1) DOP2012000063A (en)
EA (1) EA201200473A1 (en)
EC (1) ECSP12011716A (en)
IL (1) IL218390A0 (en)
IN (1) IN2012DN02081A (en)
MA (1) MA33566B1 (en)
MX (1) MX2012002977A (en)
NZ (1) NZ598643A (en)
PE (1) PE20121180A1 (en)
PH (1) PH12012500497A1 (en)
SG (1) SG178919A1 (en)
TN (1) TN2012000108A1 (en)
TW (1) TW201111378A (en)
UY (1) UY32882A (en)
WO (1) WO2011029537A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011216404B2 (en) 2010-02-17 2016-04-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2011150457A2 (en) * 2010-06-01 2011-12-08 The University Of Queensland Haematopoietic-prostaglandin d2 synthase inhibitors
AU2012358803C1 (en) 2011-12-22 2019-12-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
MX2014014323A (en) 2012-05-25 2015-02-12 Janssen R & D Ireland Uracyl spirooxetane nucleosides.
TW201418243A (en) 2012-11-15 2014-05-16 Bayer Pharma AG N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group
JP6284547B2 (en) 2012-12-21 2018-02-28 アリオス バイオファーマ インク． Substituted nucleosides, substituted nucleotides and analogs thereof
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
CN104341351B (en) * 2013-07-30 2018-02-06 北京海美源医药科技有限公司 A kind of Diarylthiohydantoin derivative and its application
LT3080100T (en) * 2013-12-11 2023-02-27 Celgene Quanticel Research, Inc. LYSINE-SPECIFIC DEMETHYLASE-1 INHIBITORS
US20160318897A1 (en) 2013-12-18 2016-11-03 Basf Se Azole compounds carrying an imine-derived substituent
US9682960B2 (en) * 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
CN103896847B (en) * 2014-04-09 2016-01-20 沈江 A kind of nonsteroidal Anti-androgenic compounds and its preparation method and application
JP6479854B2 (en) 2014-05-07 2019-03-06 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ Sulfoxyimine substituted quinazolines for pharmaceutical compositions
TWI700283B (en) 2014-08-04 2020-08-01 德商拜耳製藥公司 2-(morpholin-4-yl)-1,7-naphthyridines
CN106187905B (en) * 2015-05-05 2020-02-21 北京海步医药科技股份有限公司 Crystalline forms of bufutamide and methods of making the same
JP6888000B2 (en) 2015-10-08 2021-06-16 バイエル ファーマ アクチエンゲゼルシャフト New modified macrocycle
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
EP3601236A1 (en) 2017-03-28 2020-02-05 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
ES2900199T3 (en) 2017-03-28 2022-03-16 Bayer Ag Novel PTEFB-inhibiting macrocyclic compounds
TW201900604A (en) 2017-05-18 2019-01-01 印度商Ｐｉ工業公司 Novel bismuth compound
US11701347B2 (en) 2018-02-13 2023-07-18 Bayer Aktiengesellschaft Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for treating diffuse large B-cell lymphoma
WO2020209933A1 (en) * 2019-04-11 2020-10-15 University Of Miami Improved inhibitors of the notch transcriptional activation complex and methods for use of the same
EP4093512A1 (en) * 2020-01-21 2022-11-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Aryl hydantoin heterocycles and methods of use
CN117120436A (en) * 2021-03-30 2023-11-24 苏州开拓药业股份有限公司 A one-step method for synthesizing hydantoin thiourea derivatives
WO2025103470A1 (en) * 2023-11-17 2025-05-22 中国药科大学 Compound as androgen receptor (ar) antagonist and use thereof
CN120309588B (en) * 2025-06-10 2025-08-12 上海健康医学院 Thiohydantoin compound with androgen receptor and histone deacetylase 6 dual inhibition effect and application thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693461B1 (en) * 1992-07-08 1994-09-02 Roussel Uclaf New substituted phenylimidazolidines, process for their preparation, their use as medicaments and the pharmaceutical compositions containing them.
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (en) 1991-01-09 1993-03-26 Roussel Uclaf NOVEL PHENYLIMIDAZOLIDINES, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2694290B1 (en) 1992-07-08 1994-09-02 Roussel Uclaf New phenylimidazolidines which may be substituted, their preparation process, their use as medicaments and the pharmaceutical compositions containing them.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (en) 1994-02-16 1996-04-05 Roussel Uclaf Cosmetic or pharmaceutical compositions comprising liposomes.
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
KR100660309B1 (en) 1998-09-22 2006-12-22 아스텔라스세이야쿠 가부시키가이샤 Cyanophenyl derivative
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CA2482382A1 (en) 2002-04-12 2003-10-23 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
CA2529292A1 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Oxazolidinone antibiotics and derivatives thereof
TW200526637A (en) 2003-09-30 2005-08-16 Janssen Pharmaceutica Nv Benzoimidazole compounds
HRP20100675T1 (en) 2003-12-23 2011-01-31 Astex Therapeutics Limited DERIVATI PIRAZOLA KAO MODULATORI PROTEIN KINAZE
ATE503746T1 (en) 2004-08-03 2011-04-15 Chugai Pharmaceutical Co Ltd NEW IMIDAZOLIDINE DERIVATIVES
CN101676270A (en) * 2004-09-09 2010-03-24 中外制药株式会社 Novel tetrahydroimidazole derivatives and use thereof
WO2006058649A1 (en) 2004-12-03 2006-06-08 F. Hoffmann-La Roche Ag 3-substituted pyridine derivatives as h3 antagonists
RS52274B2 (en) 2005-05-13 2018-05-31 Univ California Diarzlhzdantoin compound
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
CA2648139A1 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
US8680291B2 (en) 2007-10-26 2014-03-25 The Regents Of The University Of California Diarylhydantoin compounds
WO2009097995A1 (en) * 2008-02-07 2009-08-13 Sanofi-Aventis Novel phenyl-substituted imidazolidines, method for the production thereof, medicaments containing said compounds and use thereof

Also Published As

Publication number Publication date
BR112012005526A2 (en) 2016-04-26
DOP2012000063A (en) 2012-05-15
US20120251551A1 (en) 2012-10-04
AR078166A1 (en) 2011-10-19
JP2013504523A (en) 2013-02-07
MA33566B1 (en) 2012-09-01
MX2012002977A (en) 2012-04-30
CL2012000623A1 (en) 2012-09-14
PE20121180A1 (en) 2012-08-24
TN2012000108A1 (en) 2013-09-19
IL218390A0 (en) 2012-04-30
ECSP12011716A (en) 2012-04-30
CU20120042A7 (en) 2012-06-21
NZ598643A (en) 2013-10-25
CO6511228A2 (en) 2012-08-31
CA2773591A1 (en) 2011-03-17
AU2010294588A1 (en) 2012-04-05
CR20120113A (en) 2012-05-02
CN102639523A (en) 2012-08-15
EA201200473A1 (en) 2012-10-30
EP2475653A1 (en) 2012-07-18
WO2011029537A1 (en) 2011-03-17
UY32882A (en) 2011-04-29
PH12012500497A1 (en) 2012-10-22
KR20120065396A (en) 2012-06-20
TW201111378A (en) 2011-04-01
SG178919A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
IN2012DN02081A (en)
CA2871471C (en) Dna-pk inhibitors
EA020330B3 (en) Quinazoline compounds
MX2011007930A (en) Crystalline insulin-conjugates.
PH12013500299B1 (en) Pyrrolopyrimidine compounds and uses thereof
MX2014004861A (en) Anticancer benzopyrazines via the inhibition of fgfr kinases.
PH12014500867A1 (en) Anticancer pyridopyrazines via the inhibition of fgfr kinases
PH12013501600A1 (en) Novel heterocyclic derivatives
BR112013033182A2 (en) substituted imidazopyridinyl aminopyridine compounds
MY189427A (en) Pyrazolyl quinoxaline kinase inhibitors
MX349004B (en) New compounds.
MX2012001419A (en) Novel bicyclic urea compounds.
MX2012010434A (en) Novel compounds and compositions for targeting cancer stem cells.
MX2014013090A (en) Pyrrolotriazinone derivatives.
MX2012001413A (en) Novel azaheterocyclic compounds.
MX2011013032A (en) Inhibitors of phosphatidylinositol 3-kinase.
MX342947B (en) Treatment of type 2 diabetes.
MX2011008645A (en) Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase.
MX2011013324A (en) Use of substituted oxindole derivatives for the treatment and prophylaxis of pain.
WO2011084523A3 (en) Ulk1 compositions, inhibitors, screening and methods of use
WO2009151495A3 (en) Oxazole compounds, compositions and methods of use
MX2013002446A (en) Substituted tetrahydropyrrolopyrazine derivatives.
TN2010000463A1 (en) Compositions and methods for preparing and using same
UA106224C2 (en) Crystalline insulin-conjugates
TN2013000327A1 (en) Novel heterocyclic derivatives